August 2020
Effectiveness of Mid-Regional Pro-Adrenomedullin (MR-proADM) as Prognostic Marker in COVID-19 Critically Ill Patients: an Observational Prospective Study
Due to the lack of validated biomarkers to predict disease progression and mortality in COVID-19 ICU-patients, we tested the effectiveness of mid-regional pro-adrenomedullin (MR-proADM) in comparison to C-reactive protein (CRP), procalcitonin (PCT), D-dimer, lactate dehydrogenase (LDH) in predicting outcome.
July 2020
Adrenomedullin in COVID-19 induced endotheliitis
Despite the exponential growth in research following the rapid spread of SARS-CoV-2 and subsequent COVID-19 pandemic, the underlying pathophysiological mechanisms in COVID-19 patients remain poorly understood. The increased incidence of cardiovascular and thromboembolic complications, immune cell deactivation and sepsis-like multiple organ failure suggests the involvement of multiple pathways.
Adrenomedullin in COVID-19 induced endotheliitis >
April 2020
COVID-19 and scarce hospital resources: B·R·A·H·M·S MR-proADM for risk stratification to support decisions on the required level of care
The biomarker mid-regional proadrenomedullin (MR-proADM) allows an easier and more accurate risk assessment in pneumonia patients compared to standard clinical scores (e.g. SOFA), independent of etiology, i.e. viral, bacterial or combined infection. Thus, MR-proADM testing is a useful tool to improve early detection of organ dysfunction and progression to sepsis and septic shock. In conjunction with clinical evaluation and other laboratory findings, MR-proADM can be used as an aid to support decision on patient disposition.
MR-proADM in Suspected Infection
Sepsis / Emergency Department (ED)
